Latest Conference Coverage

A late-breaking poster has suggested that the use of disease-modifying therapy is safe in patients with MS over the age of 65, as well as that disability burden and relapse rates may be lower than believed.

The professor of medicine and community health sciences at the University of Manitoba spoke about the effects of comorbidity on diagnosis, outcomes, and treatment in multiple sclerosis.

The professor of neurology at Harvard Medical School provided some insight into her experience with treating pediatric patients with MS.

Despite accessibility to antiepileptic drugs in high-income settings, more than one-third of patients with newly diagnosed epilepsy were not treated or had delayed treatment.

The director of the Pediatric Epilepsy Center at UCSF Benioff Children’s Hospital discussed the efficacy profile of ZX008, for which Zogenix recently submitted a new drug application to the FDA for the treatment of Dravet syndrome.

The neurologist and epileptologist at the Mayo Clinic in Jacksonville discussed when to best perform routine EEG in patients with epilepsy.

The attending neurologist at Brigham and Women's Hospital spoke about data from an analysis that concluded that women with frontal lobe epilepsy are more likely to experience a worsening of their seizure frequency during pregnancy.

The director of the MedStar Georgetown University Hospital Headache Center discussed the importance of understanding the biologic mechanisms of migraine for patients and providers.

The pediatric epileptologist at Nicklaus Children’s Hospital discussed the long-term seizure freedom data that looked at the effectiveness of perampanel which demonstrated a gratifying response in seizure control for patients with secondarily generalized seizures.

The Director of the Pediatric Epilepsy Center at UCSF Benioff Children's Hospital spoke about what defines a "clinically meaningful change in seizure frequency" using data from a phase 3 clinical trial of ZX008 for the adjunctive treatment of seizures associated with Dravet syndrome.

Uliel-Sibony discussed her and her colleagues' study of CBD, and its findings on when tolerance develops for which patient population.

The professor and vice chair of the neurology department at UCLA discussed the new VNS, RNS and DBS CPT codes for 2019.

The Clinical Fellow in Neurophysiology and Epilepsy at Massachusetts General Hospital spoke about the implications of this assessment of SUDEP.

Liu discussed this work and the findings of this proof-of-principle trial in memory in epilepsy.

The attending neurologist at Brigham and Women's Hospital spoke about how seizure frequency during pregnancy and postpartum varies by epilepsy type.

The principal medical science director at Genentech spoke about the decisions behind the tools being used for measurement, and what the neurologists can get from the data.

The Director of the cEEG and Epilepsy Consult Service at the Cleveland Clinic Epilepsy Center spoke about when clinicians should initiate and stop anti-seizure medications.

The Director of the cEEG and Epilepsy Consult Service at the Cleveland Clinic Epilepsy Center spoke about the cautious for physicians treating patients with acute symptomatic seizures.

The pediatric epileptologist at Nicklaus Children’s Hospital spoke about the long-term seizure freedom data that showed that perampanel was associated with a sustained or increased improvement in seizure control.

The professor of pediatrics at Tel Aviv University explained what has been fleshed out by the research and shared his opinion on cannabidiol’s use.

The head of the Children’s Brain Dynamics Laboratory at Boston Children’s Hospital discussed the HOPE project and its goals moving forward.

The pediatric epileptologist and adjunct professor of pediatrics at the University of Calgary spoke about how drastically things have changed surrounding the patient-physician conversation about SUDEP.

The Director of the Cleveland Clinic Epilepsy Center spoke about how important it is for clinicians to not select the wrong patients for deep brain stimulation.

The professor and head of the Department of Neurology and Rehabilitation at the University of Illinois at Chicago spoke about how data can better inform epilepsy care.

The epileptologist at the University of Pennsylvania spoke about the multiple options for patients with epilepsy and the need for a better understanding of choosing from the options.

The director of the epilepsy center at Cleveland Clinic spoke about the process that leads to the selection of candidacy for deep brain stimulation.

The director of the Epilepsy Center at Children's Health spoke about the findings of the clinical screening program, and how depression is often overlooked in patients with epilepsy.

The chief medical officer at SK Life Science discussed what makes cenobamate unique, as well as what current studies have discovered.